Biological separation dose treating femoral head ischemic necrosis

A technology for ischemic necrosis and femoral head, applied in gene therapy, genetic material components, bone diseases, etc., can solve problems such as blood supply disorder, weakening treatment effect, cell loss, etc.

Inactive Publication Date: 2008-01-23
SOUTHERN MEDICAL UNIVERSITY
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, low perfusion and low cell survival rate in the transplanted area are important factors that weaken the therapeutic effect; moreover, the root cause of ANFH is blood supply disorder, and the development of the disease course will cause further blood supply disorder, leading to the aggravation of ANFH, which is a malignant disease. In the pathogenesis of the circulation, only the induction of new blood vessels and the establishment of new

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biological separation dose treating femoral head ischemic necrosis
  • Biological separation dose treating femoral head ischemic necrosis
  • Biological separation dose treating femoral head ischemic necrosis

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

[0036] The composition of the biological dispensing agent of the present embodiment is as follows:

[0037] (1) Reagent I: a mixed aqueous solution of fibrinogen and aprotinin, wherein the content of fibrinogen is 80 mg / mL, and the content of aprotinin is 2000 KIU / mL;

[0038] (2) Reagent II: thrombin and CaCl 2 A mixed aqueous solution, in which the content of thrombin is 400IU / mL, CaCl 2 The content is 40mmol / mL;

[0039] (3) Reagent III: transgenic bone marrow stromal stem cells, the exogenous gene contained therein is the gene encoding human hepatocyte growth factor.

[0040] Among them, reagent I is obtained by mixing fibrinogen and aprotinin with water according to the ratio; reagent II is obtained by mixing thrombin and CaCl 2 It is obtained by mixing with water according to the proportion;

[0041] The preparation method of reagent III is:

[0042] 1. Using AdMax system to prepare recombinant adenovirus Ad-HGF

[0043] (1) Construct the shuttle plasmid pDC316 / HGF...

preparation example 2

[0155] The composition of the biological dispensing agent of the present embodiment is as follows:

[0156] (1) Reagent I: a mixed aqueous solution of fibrinogen and aprotinin, wherein the content of fibrinogen is 60 mg / mL, and the content of aprotinin is 1000 KIU / mL;

[0157] (2) Reagent II: thrombin and CaCl 2 A mixed aqueous solution, in which the content of thrombin is 250IU / mL, CaCl 2 The content is 40mmol / mL;

[0158] (3) Reagent III: transgenic bone marrow stromal stem cells, the exogenous gene contained therein is the gene encoding human hepatocyte growth factor.

[0159] Wherein, the preparation method of reagent III is the same as that of Example 1; reagent I is obtained by mixing fibrinogen and aprotinin with water according to the proportion; reagent II is obtained by mixing thrombin and CaCl 2 It is obtained by mixing with water according to the proportion.

preparation example 3

[0161] The composition of the biological dispensing agent of the present embodiment is as follows:

[0162] (1) Reagent I: a mixed aqueous solution of fibrinogen and aprotinin, wherein the content of fibrinogen is 100 mg / mL, and the content of aprotinin is 3000 KIU / mL;

[0163] (2) Reagent II: thrombin and CaCl 2 The mixed aqueous solution, wherein the content of thrombin is 500IU / mL, CaCl 2 The content is CaCl 2 40mmol / mL;

[0164] (3) Reagent III: transgenic bone marrow stromal stem cells, the exogenous gene contained therein is the gene encoding human hepatocyte growth factor.

[0165] Wherein, the preparation method of reagent III is the same as that of Example 1; reagent I is obtained by mixing fibrinogen and aprotinin with water according to the proportion; reagent II is obtained by mixing thrombin and CaCl 2 It is obtained by mixing with water according to the proportion.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a biological packed agent to treat early avascular necrosis of femur head, which is mainly composed of fibrinogen, prothrombin and the bone marrow stromal stem cells of the transferred HGF gene. The reagents are injected into the rabbit femoral necrosis through the decompression tunnel with the duplex injector by the core decompression technology. The fibrinogen forms a three-dimensional network structure gel and then becomes the stent for transfer HFG gene bone marrow stromal cells and controls the cell secretion HFC slow release to prevent the loss of the transplanted transgenic bone marrow stromal cell under the effect of the prothrombin. In this way, the agent can keep HGF partial effect density and improve the blood vessel regeneration and bone reconstruction in the necrosis area.

Description

technical field [0001] The invention relates to a preparation for treatment, in particular to a medical preparation for treating early avascular necrosis of the femoral head. Background technique [0002] Bone marrow stromal cells (BMSCs) are a kind of mesenchymal stem cells isolated from bone marrow with multiple differentiation potentials. In addition, BMSCs components contain osteoprogenitor cells, which have a good potential to differentiate into osteoblasts. Induced, it can differentiate into osteoblasts; the main differentiation environment in the body is bone marrow and cancellous bone trabecular bone. Differentiation into osteoblasts is considered to be the most promising seed cell for clinical application in the recent stage of bone tissue engineering. At present, the use of autologous BMSCs in the treatment of early stage (Ficat I, II) avascular necrosis of the femoral head (ANFH) has shown attractive application prospects. In 2006, Wang Wuzhou et al. treated 19...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K48/00A61K38/48A61P19/08
Inventor 马骊
Owner SOUTHERN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap